FDA approves Halozyme’s VYVGART Hytrulo for CIDP treatment
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approval of VYVGART Hytrulo (efgartigimod alfa and ... Read More
Halozyme Therapeutics announces licensing deal with Acumen Pharmaceuticals for Alzheimer’s therapy advancement
Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership focuses on utilizing Halozyme's ENHANZE drug delivery ... Read More
Halozyme Therapeutics to acquire specialty pharma company Antares Pharma for $960m
Halozyme Therapeutics, a California-based publicly-listed biotech company, has agreed to acquire New Jersey-based specialty pharma company Antares Pharma for around $960 million with an objective ... Read More